Table 3.

Comparison of BMD measurements between groups during the 12-month study period.

	Group	Baseline	12 months	p-Valuewg	% change SP	Adjusted 12 months
BMD L1-L4	Denosumab	1.002 ± 0.156a	1.060 ± 0.174	<0.005	5.76% ± 3.44b	1.125 ± 0.013a
	Zoledronate	1.000 ± 0.140a	1.051 ± 0.138	0.001	5.43% ± 3.60b	1.120 ± 0.014a
	Control	1.200 ± 0.166	1.162 ± 0.117	0.044	−2.58% ± 4.12	1.050 ± 0.013
	p-Valuebg	0.003	0.112		<0.005	0.002
BMD FN	Denosumab	0.748 ± 0.04b	0.771 ± 0.04b	<0.005	3.01% ± 2.46	0.856 ± 0.010
	Zoledronate	0.763 ± 0.04b	0.818 ± 0.06b	0.003	7.23% ± 5.46b, c	0.889 ± 0.011a
	Control	0.963 ± 0.08	0.974 ± 0.09	0.063	1.22% ± 2.09	0.845 ± 0.013
	p-Valuebg	<0.005	<0.005		0.010	0.013

BMD: bone mineral density; bg: between group; wg: within group; SP: study period, baseline-12 months.

Adjusted for baseline measurements.

^ap < 0.05 vs. control.

^bp < 0.005 vs. control.

^cp < 0.05 vs. Denosumab.